A real-world, multicenter assessment of drugs requiring weight-based calculations in overweight, adult critically ill patients

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Kane Gill, Sandra L ^a,b   Wytiaz, Nicholas P ^c   Thompson, Lisa M ^d   Muzykovsky, Karina ^e   Buckley, Mitchell S ^f   Cohen, Henry ^g,h   Seybert, Amy L ^b,i  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c WESTERN PENNSYLVANIA HOSPITAL   (United States)

^d Banner MD Anderson Cancer Center   (United States)

^e BROOKLYN HOSPITAL CENTER   (United States)

^f BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^g LONG ISLAND UNIVERSITY   (United States)

^h KINGSBROOK JEWISH MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CRITICAL ILLNESS; DOSE RESPONSE; DRUG THERAPY; HUMAN; METHODOLOGY; MULTICENTER STUDY; OBESITY; PROSPECTIVE STUDY;

ADULT; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; OVERWEIGHT; PROSPECTIVE STUDIES;

EID: 84893823727     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/909135     Document Type: Article

References (47)

1. Flegal K. M., Carroll M. D., Ogden C. L., Curtin L. R., Prevalence and trends in obesity among US adults, 1999-2008. Journal of the American Medical Association 2010 303 3 235 241 2-s2.0-74549140993 10.1001/jama.2009.2014
2. Hart C. L., Hole D. J., Lawlor D. A., Smith G. D., Obesity and use of acute hospital services in participants of the Renfrew/Paisley study. Journal of Public Health 2007 29 1 53 56 2-s2.0-33847352954 10.1093/jpubhealth/fdl088
3. Tarride J.-E., Haq M., Taylor V. H., Sharma A. M., Nakhai-Pour H. R., O'Reilly D., Xie F., Dolovich L., Goeree R., Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada. ClinicoEconomics and Outcomes Research 2012 4 1 21 30 2-s2.0-84856809324
4. Erstad B. L., Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Medicine 2004 30 1 18 32 2-s2.0-0742269741 10.1007/s00134-003-2059-6 (Pubitemid 38147104)
5. Mueller S. W., MacLaren R., Kane-Gill S. L., Dasta J. F., Vasopressors and Inotropes. High-Risk IV Medications in Special Patient Populations 2011 London, UK Springer 69 96
6. Coons J. C., Devabhakthuni S., Kane-Gill S. L., Dasta J. F., Thrombolytics/Anticoagulants. High-Risk IV Medications in Special Patient Populations 2011 London, UK Springer 1 67
7. Devlin J. W., Kane-Gill S. L., Dasta J. F., Sedatives. High-Risk IV Medications in Special Patient Populations 2011 London, UK Springer 97 114
8. LeBlanc J. M., Obritsch M. D., Kane-Gill S. L., Dasta J. F., Analgesics and neuromuscular blockers. High-Risk IV Medications in Special Patient Populations 2011 London, UK Springer 115 138
9. Pai M. P., Bearden D. T., Antimicrobial dosing considerations in obese adult patients: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2007 27 8 1081 1091 2-s2.0-34547431719 10.1592/phco.27.8.1081 (Pubitemid 47173654)
10. ISMP's List of High Alert Medications, Institute for Safe Medication Practices. 2012, http://www.ismp.org/Tools/highalertmedications.pdf
11. Dobutamine Hydrochloride Injection [Package Insert] April 2006 Lake Forest, Ill, USA Hospira
12. Dopamine Hydrochloride Injection [Package Insert] October 2004 Lake Forest, Ill, USA Hospira
13. Milrinone Lactate Injection [Package Insert] January 2008 Deerfield, Ill, USA Baxter Healthcare Corporation
14. Nitroglycerin Injection [Package Insert] November 2005 Shirley, NY, USA American Regent
15. Norepinephrine Bitartrate Injection [Package Insert] October 2009 Bedford, Ohio, USA Bedford Laboratories
16. Phenylephrine HCL Injection [Package Insert] November 2005 Shirley, NY, USA American Regent
17. Heparin Sodium, Injection [Package Insert] July 2012 Lake Forest, Ill, USA Hospira
18. Hirsh J., Guyatt G., Albers G. W., Harrington R., Schünemann H. J., Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 supplement 6 110s 112s 2-s2.0-45949108549 10.1378/chest.08-0652 (Pubitemid 351892962)
19. Diprivan (Propofol) Injection, Emulsion [Package Insert] August 2007 Wilmington, Del, USA AstraZeneca Pharmaceuticals LP
20. Midazolam Hydrochloride Injection [Package Insert] July 2011 Wilmington, Del, USA Hospira, Lake Forest, Ill, USA; Pharmaceuticals Laboratories
21. Fentanyl Citrate Injection [Package Insert] October 2011 Eatontown, NJ, USA Westward Pharmaceuticals
22. Rocuronium Bromide Injection [Package Insert] April 2011 LLC. Schaumburg, Ill, USA APP Pharmaceuticals
23. Goh C. L., An approach to the evaluation and documentation of adverse drug reaction. Singapore Medical Journal 1989 30 3 285 289 2-s2.0-0024676224
24. Naranjo C. A., Busto U., Sellers E. M., A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics 1981 30 2 239 245 2-s2.0-0019799332 (Pubitemid 12149145)
25. Jones J. K., Definition of events associated with drugs: regulatory perspectives. Journal of Rheumatology 1988 15 17 14 19 2-s2.0-0023796253 (Pubitemid 18261072)
26. Kane-Gill S. L., Visweswaran S., Saul M. I., Wong A.-K. I., Penrod L. E., Handler S. M., Computerized detection of adverse drug reactions in the medical intensive care unit. International Journal of Medical Informatics 2011 80 8 570 578 2-s2.0-79960069551 10.1016/j.ijmedinf.2011.04.005
27. Kramer M. S., Leventhal J. M., Hutchinson T. A., Feinstein A. R., An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. Journal of the American Medical Association 1979 242 7 623 632 2-s2.0-0018645590 10.1001/jama.242.7.623 (Pubitemid 9252462)
28. Cockcroft D. W., Gault M. H., Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 1 31 41 2-s2.0-0016916438
29. World Health Organization, Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization. Technical Report Series 2000 894 1 253
30. National Institutes of Health, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obesity Research 1998 6 supplement 2 51S 209S
31. Grace E., Goodbar Hope N., Foushee J. A., optimizing vancomycin dosing in obese and morbidly obese patients with MRSA infections. Advances in Pharmacoepidemiology and Drug Safety 2012 S1
32. Longo C., Bartlett G., MacGibbon B., The effect of obesity on antibiotic treatment failure: A Historical Cohort Study. Pharmacoepidemiology and Drug Safety 2013 22 970 976
33. Pai M. P., Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012 32 856 868
34. Kane-Gill S. L., Kirisci L., Verrico M. M., Rothschild J. M., Analysis of risk factors for adverse drug events in critically ill patients. Critical Care Medicine 2012 40 3 823 828 2-s2.0-84857562169 10.1097/CCM.0b013e318236f473
35. Yee W. P., Norton L. L., Optimal weight base for a weight-based heparin dosing protocol. American Journal of Health-System Pharmacy 1998 55 2 159 162 2-s2.0-0031937523 (Pubitemid 28067134)
36. Spruill W. J., Wade W. E., Huckaby W. G., Leslie R. B., Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. American Journal of Health-System Pharmacy 2001 58 22 2143 2146 2-s2.0-0035890018 (Pubitemid 33065007)
37. Joncas S. X., Poirier P., Ardilouze J. L., Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. Obesity 2013 21 9 1753 1758 10.1002/oby.20029
38. Hurewitz A. N., Khan S. U., Groth M. L., Patrick P. A., Brand D. A., Dosing of unfractionated heparin in obese patients with venous thromboembolism. Journal of General Internal Medicine 2011 26 5 487 491 2-s2.0-79958717135 10.1007/s11606-010-1551-2
39. Wheeler A. P., Jaquiss R. D. B., Newman J. H., Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Archives of Internal Medicine 1988 148 6 1321 1325 2-s2.0-0023913277
40. Kearon C., Kahn S. R., Agnelli G., American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008 133 454S 545S (Pubitemid 351892971)
41. Devlin J. W., Roberts R. J., Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Critical Care Clinics 2009 25 3 431 449 2-s2.0-67649304470 10.1016/j.ccc.2009.03.003
42. Spina S. P., Ensom M. H. H., Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 2007 27 3 389 398 2-s2.0-33847254988 10.1592/phco.27.3.389 (Pubitemid 46327906)
43. McLeay S. C., Morrish G. A., Kirkpatrick C. M., Green B., Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharmaceutical Research 2009 26 7 1626 1634 2-s2.0-67349243866 10.1007/s11095-009-9873-7
44. Barr J., Fraser G. L., Puntillo K., Clinical practice guidelines for the management of pain, agitation and delirium in adult patients in the intensive care unit. Critical Care Medicine 2013 41 263 306
45. El Sohl A. A., Deutschman C. S., Neligan P. J., Trauma, obstetrics, and environmental injuries. Evidence-Based Practice of Critical Care 2010 Elsevier Health Sciences 618 626
46. Meyhoff C. S., Lund J., Jenstrup M. T., Claudius C., Sørensen A. M., Viby-Mogensen J., Rasmussen L. S., Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesthesia and Analgesia 2009 109 3 787 792 2-s2.0-70149124339 10.1213/ane.0b013e3181b0826a
47. Omori D. M., Potyk R. P., Kroenke K., The adverse effects of hospitalization on drug regimens. Archives of Internal Medicine 1991 151 8 1562 1564 2-s2.0-0025863570 10.1001/archinte.151.8.1562